I wish to comment on several points in the recent "Guidelines".
Drew
W Lawrence
WL
D000368:Aged; D000547:Amantadine / Q000009:adverse effects / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D006801:Humans; D009980:Influenza A virus / Q000187:drug effects* / Q000302:isolation & purification; D009981:Influenza B virus / Q000187:drug effects* / Q000302:isolation & purification; D007251:Influenza, Human / Q000188:drug therapy* / Q000821:virology; D012299:Rimantadine / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D012299:Rimantadine; D000547:Amantadine